Skip to main content

All products are sold strictly for laboratory research use only. Not for human or veterinary consumption, diagnosis, or treatment. Not approved by the FDA.

Research Use Only
RIBOCORE
Browse ProductsMost PopularPurity ReportsResearchResearch Use OnlySupport
0
RIBOCORE

Research-use-only peptides, compounds, and analytical documentation for qualified laboratories and institutions.

Products

  • Catalog
  • Most Popular
  • New Releases
  • Bundles

Trust

  • Purity Reports
  • Quality & Testing
  • Research Blog
  • Research Use Only
  • Shipping Policy
  • Discreet Delivery
  • Guarantee
  • Support Center

Stay Updated

Join our researcher list for batch alerts and purity report updates.

© 2026 RIBOCORE ANALYTICAL. ALL PRODUCTS SOLD STRICTLY FOR LABORATORY RESEARCH USE ONLY.
PrivacyTerms of ServiceShippingResearch Use OnlyPurity Reports

Search results for "Lyophilized peptide"

Found 83 products

Categories

  • GLP-1 & Weight Management(22)
  • Recovery & Healing(7)
  • Growth Hormone Peptides(13)
  • Anti-Aging & Wellness(20)
  • Supplies & Accessories(24)
  • Bundles(4)

Brand

83 results

Cagrilintide (5mg) / Tirz (10mg)
99.4% Purity
In Stock
-25%

Cagrilintide (5mg) / Tirz (10mg)

  • Triple-Receptor Agonist: Combines amylin, GIP, and GLP-1 pathways in one formulation
  • Multi-Pathway Engagement: Three independent satiety and metabolic control mechanisms
  • Research Blend: 5mg Cagrilintide + 10mg Tirzepatide, ≥98% purity each component
$199.00

$149.00

Thymosin Alpha-1
99.4% Purity
In Stock

Thymosin Alpha-1

  • 28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
  • Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
  • Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction

$49.00

TB-500 (Thymosin Beta-4) (43aa)
99.4% Purity
In Stock

TB-500 (Thymosin Beta-4) (43aa)

  • Thymosin Beta-4 Derivative: 43-amino acid peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH), derived from naturally occurring thymosin beta-4 (70-80% of beta-thymosins), 2,000+ publications, N-terminal acetylation for enhanced stability
  • Multi-Pathway Regeneration: G-actin sequestration (Kd 0.5-0.7 μM), cell migration promotion, VEGF upregulation via Wnt/β-catenin/Lef-1, angiogenesis, PI3K/Akt/eNOS survival pathway, anti-fibrotic via TGF-β1 suppression
  • Clinical Status: No FDA-approved human drug, all therapeutic data preclinical (wound healing, cardiac repair, pulmonary fibrosis, Alzheimer's neuroprotection), extensive safety profile in animal models

$36.40

SNAP-8 (10mg)
99.4% Purity
In Stock

SNAP-8 (10mg)

  • SNAP-8 (Acetyl Octapeptide-3) is an 8-amino acid biomimetic peptide (Ac-EEMQRRAD-NH2) that competitively inhibits SNAP-25 incorporation into the SNARE complex, achieving ~43% inhibition of glutamate release
  • Developed as a topical alternative to botulinum toxin, it provides muscle relaxation (not paralysis) with reversible, dose-dependent modulation of neurotransmitter release

$33.00

SLU-PP-332 Capsules (250mcg) 100 Count
99.4% Purity
In Stock

SLU-PP-332 Capsules (250mcg) 100 Count

  • Pan-ERR Agonist Exercise Mimetic: Hydrazone small molecule (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide, Saint Louis University design, activates ERRalpha/beta/gamma (EC50 98/230/430 nM), 10+ publications, all preclinical
  • Multi-System Metabolic Reprogramming: 70% increased endurance, 12% body weight loss, mitochondrial biogenesis via PGC-1alpha/AMPK/TFAM cascade, type IIa muscle fiber conversion, 25% increased fatty acid oxidation, reverses age-related kidney dysfunction
  • Clinical Status: No human trials (as of Feb 2026), all data from mouse models, well-tolerated in 8-week studies, successor compound SLU-PP-915 with improved oral bioavailability developed 2026

$89.00

Semax 30mg
99.4% Purity
In Stock

Semax 30mg

  • ACTH(4-10) Analogue: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, developed 1982 Russian Academy, ACTH(4-7) + Pro-Gly-Pro extension for metabolic stability, 800+ publications, no hormonal activity
  • Multi-Modal Neuroprotection: BDNF upregulation (1.4× protein, 3× mRNA hippocampus), monoamine modulation (180% 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity, transcriptomic ischemia protection
  • Clinical Status: Russian FDA approved, List of Vital & Essential Drugs 2011, Phase I-II trials 1990-1996, extensive clinical use for stroke/cognitive disorders/optic neuropathy, low toxicity profile

$30.00

Semaglutide Capsules (500mcg) 25 Count
99.4% Purity
In Stock

Semaglutide Capsules (500mcg) 25 Count

  • Oral semaglutide is a 31-amino acid GLP-1 receptor agonist with engineered modifications (Aib8, C-18 fatty di-acid, Lys34Arg) enabling oral bioavailability via SNAC absorption enhancement technology
  • Research demonstrates glycemic control comparable to injectable GLP-1 agonists with 15
  • 1% weight loss (50mg dose, OASIS-1 trial)

$99.00

Vial Storage
99.4% Purity
In Stock

Vial Storage

  • Profile: Vial storage container for research peptides
  • Quality: >=95% Purity (HPLC Verified)

$4.00

Selank 10mg
99.4% Purity
In Stock

Selank 10mg

  • Synthetic Tuftsin Analogue: Heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed Russian Academy of Sciences, tuftsin core + Pro-Gly-Pro extension for metabolic stability, 20+ years research
  • Multi-Modal Mechanism: Positive allosteric modulator of GABA-A receptors, upregulates BDNF (hippocampus/cortex), inhibits enkephalinase (IC50 15 μM), modulates monoamines, no tolerance/dependence
  • Clinical Status: Russian FDA approved 2009 for GAD/neurasthenia (intranasal 0.15%), RCT showed efficacy equal to medazepam with additional nootropic effects, no sedation/amnesia unlike benzodiazepines

$40.00

Reconstitution Solution (10ml)
99.4% Purity
In Stock

Reconstitution Solution (10ml)

  • Profile: Sterile bacteriostatic water for peptide reconstitution
  • Quality: >=95% Purity (HPLC Verified)

$9.60

Rad140 Capsules (15mg) 60 Count
99.4% Purity
In Stock
-17%

Rad140 Capsules (15mg) 60 Count

  • Nonsteroidal SARM: Benzonitrile-oxadiazole scaffold with AR binding Ki 7 nM (comparable to DHT 10 nM), first described 2011, tissue-selective levator ani vs. prostate activity, oral bioavailability 27-75%
  • Clinical Development: Phase 1 ER+/HER2- breast cancer (MTD 100 mg/day, t½ 44.7 hours), active Phase 1/2 trial (NCT05573126, Ellipses Pharma EP0062), discontinued for sarcopenia indications
  • Safety Warnings: Dose-limiting hepatotoxicity (AST 59.1%, ALT 45.5%), cholestatic liver injury case reports, cardiotoxicity (myocarditis/myopericarditis), HPG axis suppression, WADA prohibited S1.2, not approved for medical use
$119.00

$99.00

PT-141 10mg
99.4% Purity
In Stock

PT-141 10mg

  • FDA-Approved Melanocortin Agonist: Cyclic heptapeptide MC3R/MC4R agonist, approved June 2019 (Vyleesi) for premenopausal HSDD, 100+ publications, first melanocortin therapeutic for sexual function
  • CNS Mechanism: Crosses blood-brain barrier, activates hypothalamic MC4R in mPOA triggering dopamine release, melanocortin-dopamine integration, mesolimbic reward pathway modulation
  • Clinical Development: 43 completed trials with 3,500+ subjects, Phase 3 RECONNECT (n=1,267) showed +0.35 desire improvement, 58% vs 36% responder rates, well-characterized safety profile

$33.25

Showing 1 to 12 of 83 results

1234567